NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Shanghai Leader Peptide Biotechnology

Published 12 Nov 2026. 41-page investigative report on who is behind Shanghai Leader Peptide Biotechnology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Shanghai Leader Peptide Biotechnology is a mixed, peptide-specific case rather than a simple pass/fail vendor. Across 84 Finnrick lab tests, the record shows 58 pass / 21 fail, a 69% overall pass rate. GHK-Cu and tirzepatide are the comparatively stronger rows; tesamorelin is the clearest avoid-or-verify product; retatrutide is too mixed to buy on brand confidence alone. The methodology view matters because stricter grading reduces the safety margin on thinner rows.

The document trail is the sharper concern. Leader Peptide’s public COA center is Qorix-heavy, yet Qorix’s own working verifier authenticated a control report for another supplier while returning not found for every Leader Peptide Qorix number tested. That does not prove fabrication, but it blocks public authentication of the vendor’s dominant COA source.

Corporate and operational visibility remain thin. The site uses two Chinese company-name variants and publishes no verified registry identifier, legal representative, seller of record, named QA lead or batch-release authority. Broad facility and manufacturing claims are not matched by a public permit, audit or geolocated plant evidence; this is a verification limitation, not proof that competent personnel or facilities are absent.

The channel layer adds buyer-recourse risk: a vendor-controlled Verified rep directory, AI/stock portrait evidence, a self-referential verifier and a live shipping CTA still pointing to an old UK-format WhatsApp route the verifier does not recognize. Payment disclosures emphasize quote-based ordering, sales-supplied wallets and weak public refund/terms controls.

Inside the full report:

  • Per-product Finnrick rates and methodology-divergence charts for all 8 tested products
  • Qorix verification log comparing a verified control with Leader Peptide not-found results
  • Corporate identity exhibits covering Chinese-name variants, registry dead ends and address context
  • COA-center composition across Qorix, Janoshik, Freedom, Biovan, PEPTEGRITY and unknown-lab rows
  • Sales-channel map of the 29-rep directory, AI/stock portraits and residual WhatsApp route
  • Buyer controls for invoices, payment recipients, exact-lot COAs and shipment documents

Risk assessment

  • COA authenticity / Qorix verification failure — high: 115 of 149 public COAs are Qorix documents; Qorix verified a control report but returned not_found for all 8 Leader Peptide report numbers tested, including the 2026-10-08 series.
  • Legal-entity and ownership opacity — high: No verified registry record, social credit code, legal representative, parent, UBO or legal seller was obtained; the Chinese name appears in two variants on the vendor site.
  • Manufacturing/facility verification gap — high: The site claims synthesis, purification, lyophilization, analytical testing and a 3000m² facility, but publishes no permit, audit, plant address, named QA lead or release authority.
  • Channel-authentication and brand-confusion risk — high: The 29-rep team page uses self-asserted Verified badges, AI/stock portrait evidence and a self-referential verifier; the Shipping page still links to old WhatsApp +44 7761 233386, which the verifier does not recognize.
  • Buyer recourse / transaction transparency risk — high: Quote-only flow, no public checkout, no seller-identified invoice template, no terms/refund/privacy pages and crypto wallets supplied by sales leave weak recourse after non-delivery, seizure, wrong product or failed testing.
  • Tesamorelin quality-control risk — high: Finnrick rates tesamorelin at 48.78% with 5 pass / 5 fail across 10 tests, materially weaker than this vendor’s GHK-Cu and tirzepatide rows.
  • Cagrilintide quality-control risk — medium: Finnrick rates cagrilintide at 50.97% with 1 pass / 2 fail across 3 tests; small sample, but the signal is weak/negative.
  • Retatrutide quality-control risk — medium: Finnrick rates retatrutide at 69.41% with 19 pass / 9 fail across 28 tests; the mixed record requires exact-lot verification or a stronger retatrutide-specific vendor.
  • BPC-157 quality-control risk — medium: Finnrick rates BPC-157 at 58.39% with 4 pass / 0 fail across 4 tests; no recorded failures, but rating and small sample are not enough to validate the product.
  • NAD+ quality-control risk — medium: Finnrick rates NAD+ at 30.14% with 2 pass / 0 fail across 2 tests; it is the lowest current rating and too small to support a positive inference.
  • Promotion and review-content integrity risk — medium: Brand-linked X/Telegram promotion, a matching Reddit rep-handle comment, a removed review page and same-day AI-like content-farm pages were found; paid commissioning was not proven.
  • Import/customs documentation risk — medium: Catalog includes HGH/somatropin, HCG, botulinum toxin and GLP-1s; no named exporter or customs broker was published, and no named enforcement action found is not clearance.
  • Marketing-claim integrity risk — medium: 200+ products vs 81 catalog URLs, 128+ vs 149 certificate count, COA not-yet-published pages and an unsupported IGF-1 LR3 99.6% COA claim show claim-control weaknesses.